EPS for Acorda Therapeutics, Inc. (ACOR) Expected At $0.30; 2 Analysts Bullish 3D Systems (DDD)




March 22, 2018 – By Peter Erickson

Among 19 analysts covering 3D Systems Corporation (NYSE:DDD), 2 have Buy rating, 6 Sell and 11 Hold. Therefore 11% are positive. 3D Systems Corporation had 68 analyst reports since July 22, 2015 according to SRatingsIntel. The rating was upgraded by Bank of America to “Buy” on Thursday, April 14. The firm has “Market Perform” rating by FBR Capital given on Tuesday, May 24. The stock of 3D Systems Corporation (NYSE:DDD) has “Neutral” rating given on Tuesday, March 15 by Goldman Sachs. Piper Jaffray maintained 3D Systems Corporation (NYSE:DDD) on Wednesday, March 14 with “Hold” rating. The company was maintained on Wednesday, February 7 by Piper Jaffray. As per Friday, August 7, the company rating was maintained by Stifel Nicolaus. The rating was upgraded by PiperJaffray to “Neutral” on Monday, November 20. The firm has “Sell” rating by Piper Jaffray given on Friday, October 13. Citigroup downgraded the shares of DDD in report on Friday, April 15 to “Sell” rating. The company was maintained on Tuesday, March 15 by Jefferies. See 3D Systems Corporation (NYSE:DDD) latest ratings:

16/03/2018 Broker: Susquehanna Rating: Hold New Target: $12.0 Maintain
16/03/2018 Broker: Deutsche Bank Old Rating: Hold New Rating: Hold Old Target: $9 New Target: $13 Maintain
15/03/2018 Broker: FBR Capital Rating: Sell Maintain
14/03/2018 Broker: Piper Jaffray Rating: Hold New Target: $10.0 Maintain
15/03/2018 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Hold Old Target: $11 New Target: $12 Maintain
05/03/2018 Broker: Susquehanna Rating: Hold New Target: $10.0 Maintain
01/03/2018 Broker: FBR Capital Rating: Sell Maintain
09/02/2018 Broker: J.P. Morgan Rating: Sell New Target: $11.0 Downgrade
09/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Old Target: $11 Downgrade
07/02/2018 Broker: Piper Jaffray Rating: Hold New Target: $9.5 Maintain

Analysts expect Acorda Therapeutics, Inc. (NASDAQ:ACOR) to report $0.30 EPS on April, 26.They anticipate $0.71 EPS change or 173.17% from last quarter’s $-0.41 EPS. ACOR’s profit would be $14.08 million giving it 20.00 P/E if the $0.30 EPS is correct. After having $0.45 EPS previously, Acorda Therapeutics, Inc.’s analysts see -33.33% EPS growth. The stock decreased 0.62% or $0.15 during the last trading session, reaching $24. About 5,396 shares traded. Acorda Therapeutics, Inc. (NASDAQ:ACOR) has declined 40.68% since March 22, 2017 and is downtrending. It has underperformed by 57.38% the S&P500.

Among 14 analysts covering Acorda Therapeutics (NASDAQ:ACOR), 5 have Buy rating, 1 Sell and 8 Hold. Therefore 36% are positive. Acorda Therapeutics had 43 analyst reports since August 25, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, November 15 by Cowen & Co. The stock has “Buy” rating by H.C. Wainwright on Thursday, December 14. J.P. Morgan maintained the stock with “Hold” rating in Tuesday, June 6 report. The stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) has “Hold” rating given on Tuesday, October 31 by Cantor Fitzgerald. On Tuesday, August 25 the stock rating was maintained by Stifel Nicolaus with “Buy”. The stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) earned “Hold” rating by Leerink Swann on Tuesday, August 29. The company was initiated on Wednesday, March 30 by Goldman Sachs. As per Tuesday, August 25, the company rating was maintained by JP Morgan. The firm has “Hold” rating by Janney Capital given on Wednesday, January 31. On Wednesday, November 8 the stock rating was initiated by Oppenheimer with “Hold”.

Investors sentiment decreased to 0.99 in 2017 Q3. Its down 0.23, from 1.22 in 2017Q2. It fall, as 19 investors sold Acorda Therapeutics, Inc. shares while 39 reduced holdings. 22 funds opened positions while 49 raised stakes. 51.31 million shares or 4.56% more from 49.07 million shares in 2017Q2 were reported. Citadel Lc invested in 0% or 13,107 shares. Nationwide Fund reported 146,207 shares. Moreover, Commercial Bank Of America De has 0% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 197,840 shares. Baker Bros Advsrs Limited Partnership accumulated 519,500 shares. Whittier Trust holds 36,866 shares or 0.03% of its portfolio. Amer Interest Grp holds 34,712 shares. Piedmont Advsr Lc, a North Carolina-based fund reported 10,162 shares. Geode Mngmt Ltd Liability reported 430,928 shares. Gru One Trading Lp has 0% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Ameritas Prtnrs holds 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR) or 3,713 shares. Sector Pension Investment Board has invested 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). D E Shaw & Company Inc reported 563,913 shares stake. Leucadia Natl Corporation reported 13,392 shares. Cornerstone Mngmt Holding Ltd Llc reported 25,470 shares. Morgan Stanley has 78,030 shares.

Since October 9, 2017, it had 0 insider purchases, and 3 insider sales for $1.81 million activity. Shares for $854,911 were sold by LAWRENCE DAVID on Thursday, January 18. 34,520 shares were sold by Wasman Jane, worth $952,319 on Friday, January 19.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company has market cap of $1.13 billion. The firm markets Ampyra , an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It currently has negative earnings. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.

3D Systems Corporation, through its subsidiaries, provides 3D printing services and products worldwide. The company has market cap of $1.35 billion. The companyÂ’s 3D printers transform data input generated by 3D design software, CAD software, or other 3D design tools into printed parts using a range of print materials, including plastic, nylon, metal, composite, elastomeric, wax, polymeric dental materials, and Class IV bio-compatible materials. It currently has negative earnings. It offers various 3D printing technologies, such as stereolithography, selective laser sintering, direct metal printing, multijet printing, and colorjet printing.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our daily email newsletter.




Source link

Leave a Reply